Kennedy Van der Laan has advised NuFrontiers, the strategic innovation and investment arm of Nutreco Investments B.V., a global leader in animal nutrition and aquafeed, on its investment in Israeli startup ViAqua as part of its focus on combatting disease in the aquaculture industry. ViAqua is developing the first orally-administered treatment for shrimp that improves resistance to viral diseases, including White Spot Syndrome Virus (WSSV), and prevents viral epidemics. ViAqua also signed a joint development and marketing deal with Nutreco’s aquafarming subsidiary Skretting AS. Additional investors include existing ViAqua shareholders Trendlines and the Technion – Israel Institute of Technology, a research university in Israel’s northern port city Haifa. Our team consisted of Meltem Koning-Gungormez and Maarten Schut.
Please find the press release here.
